David Hollander
CIK 1793796 · CMO & Global Therapeutics Lead · last filed 2025-04-02
David Hollander is a CMO & Global Therapeutics Lead who has filed 12 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for KPRX, was dated Apr 2, 2025. Across all open-market trades the lifetime net is −$16.3K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
12
-$16.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KPRX | Director | — | $2.55 | — | $0 | 5 | 2025-04-02 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CMO & Global Therapeutics Lead | 0 | $3.65 | $0 | -$16.3K | 2 | 2025-02-06 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Chief R&D Officer | 30,749 | $15.25 | $468.9K | $0 | 5 | 2022-02-08 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-02 | KPRX | Grant (A) | — | $0 | EDGAR |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −104,945 | -$35.5K | EDGAR |
| 2024-11-19 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −3,908 | -$16.3K | EDGAR |
| 2024-07-03 | KPRX | Grant (A) | — | $0 | EDGAR |
| 2023-10-03 | KPRX | Grant (A) | — | $0 | EDGAR |
| 2023-03-07 | KPRX | Grant (A) | — | $0 | EDGAR |
| 2022-02-08 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Tax (F) | −927 | -$6.5K | EDGAR |
| 2022-02-03 | KPRX | Grant (A) | — | $0 | EDGAR |
| 2021-11-15 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Tax (F) | −2,162 | -$26.1K | EDGAR |
| 2021-02-08 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Grant (A) | +11,000 | $0 | EDGAR |